NTLA vs CRSP
NTLA and CRSP side by side — valuation & fundamentals (public data).
Key statistics
| Metric | NTLAINTELLIA THERAPEUTICS, INC. | CRSPCRISPR THERAPEUTICS AG |
|---|---|---|
| Market cap | $1.50B | $4.79B |
| P/S | 22.2x | 1365.3x |
| Revenue growth (YoY) | 16.9% | -90.6% |
| Earnings growth (YoY) | 20.5% | -58.8% |
| EBIT margin | -651.7% | -18933.6% |
| ROE | -66.5% | -33.3% |
| ROIC | — | -32.6% |
| 1y total return | -6.2% | -11.7% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: NTLA frente a CRSP
| Métrica | NTLA | CRSP |
|---|---|---|
| Valor final | $8.5K | $35.2K |
| Retorno total | -14.6% | +251.8% |
| CAGR | -1.6% | +13.7% |
| Volatilidad | 78.7% | 64.1% |
| Sharpe | 0.32 | 0.46 |
| Sortino | 0.48 | 0.71 |
| Caída máxima | -96.5% | -85.1% |
Basado en 2459 días de negociación comunes, 2016-10-19 → 2026-08-03 · tasa libre de riesgo 3.91% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)